Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement

230 Pages·2014·2.575 MB·English

by  Jean B. Patel, PhD, D(ABMM) Franklin R. Cockerill III, MD Jeff Alder, PhD Patricia A. Bradford, PhD George M. Eliopoulos, MD Dwight J. Hardy, PhD Janet A. Hindler, MCLS, MT(ASCP) Stephen G. Jenkins, PhD, D(ABMM), F(AAM) James S. Lewis II, PharmD Linda A. Miller, PhD Mair Powell, MD, FRCP, FRCPath Jana M. Swenson, MMSc Maria M. Traczewski, BS, MT(ASCP) John D. Turnidge, MD Melvin P. Weinstein, MD Barbara L. Zimmer, PhD

January 2014
M100-S24
Performance Standards for Antimicrobial
Susceptibility Testing; Twenty-Fourth
Informational Supplement
This document provides updated tables for the Clinical and
Laboratory Standards Institute antimicrobial susceptibility testing
standards M02-A11, M07-A9, and M11-A8.
An informational supplement for global application developed through the Clinical and Laboratory Standards Institute
consensus process.
Clinical and Laboratory Standards Institute
Setting the standard for quality in clinical laboratory testing around the world.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings
together the varied perspectives and expertise of the worldwide laboratory community for the advancement of
a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory
standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and
global applicability.

Consensus Process
Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the
development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the
participants in the development of a consensus document have considered and resolved all relevant objections
and accept the resulting agreement.

Commenting on Documents
CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies,
procedures, methods, and protocols affecting the laboratory or health care.
CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as
participants in the reviewing and commenting process. At the end of each comment period, the committee that
developed the document is obligated to review all comments, respond in writing to all substantive comments,
and revise the draft document as appropriate.
Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on
any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process
If it is believed that an objection has not been adequately addressed, the process for appeals is documented in
the CLSI Standards Development Policies and Process document.
All comments and responses submitted on draft and published documents are retained on file at CLSI and are
available upon request.
Get Involved—Volunteer!
Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get
involved in the revision process? Or maybe you see a need to develop a new document for an emerging
technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and
talents to improve the standards that affect your own work, you will play an active role in improving public
health across the globe.
For further information on committee participation or to submit comments, contact CLSI.
Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
[email protected]
Vol. 34 No. 1 M100-S24

Performance Standards for Antimicrobial Susceptibility Testing;
Twenty-Fourth Informational Supplement

Abstract

The supplemental information presented in this document is intended for use with the antimicrobial
susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute
(CLSI)–approved standards: M02-A11—Performance Standards for Antimicrobial Disk Susceptibility
Tests; Approved Standard—Eleventh Edition; M07-A9—Methods for Dilution Antimicrobial
Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition; and
M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—
Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11)
test procedures for aerobic and anaerobic bacteria.

Clinicians depend heavily on information from the clinical microbiology laboratory for treatment of their
seriously ill patients. The clinical importance of antimicrobial susceptibility test results requires that these
tests be performed under optimal conditions and that laboratories have the capability to provide results for
the newest antimicrobial agents.

The tabular information presented here represents the most current information for drug selection,
interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and
M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since
the most current edition appear in boldface type.)

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility
Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24 (ISBN 1-56238-897-5
[Print]; ISBN 1-56238-898-3 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley
Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2014.

The data in the interpretive tables in this supplement are valid only if the
methodologies in M02-A11—Performance Standards for Antimicrobial Disk
Susceptibility Tests; Approved Standard—Eleventh Edition; M07-A9—Methods
for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow
Aerobically; Approved Standard—Ninth Edition; and M11-A8—Methods for
Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—
Eighth Edition are followed.
1
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
January 2014 M100-S24

2
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
ISBN 1-56238-897-5 (Print) M100-S24
ISBN 1-56238-898-3 (Electronic) Vol. 34 No. 1
ISSN 1558-6502 (Print) Replaces M100-S23
ISSN 2162-2914 (Electronic) Vol. 33No. 1
Performance Standards for Antimicrobial Susceptibility Testing;
Twenty-Fourth Informational Supplement

Volume 34 Number 1

Jean B. Patel, PhD, D(ABMM)
Franklin R. Cockerill III, MD
Jeff Alder, PhD
Patricia A. Bradford, PhD
George M. Eliopoulos, MD
Dwight J. Hardy, PhD
Janet A. Hindler, MCLS, MT(ASCP)
Stephen G. Jenkins, PhD, D(ABMM), F(AAM)
James S. Lewis II, PharmD
Linda A. Miller, PhD
Mair Powell, MD, FRCP, FRCPath
Jana M. Swenson, MMSc
Maria M. Traczewski, BS, MT(ASCP)
John D. Turnidge, MD
Melvin P. Weinstein, MD
Barbara L. Zimmer, PhD
January 2014 M100-S24

Copyright ©2014 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of
content from a CLSI copyrighted standard, guideline, companion product, or other material requires
express written consent from CLSI. All rights reserved. Interested parties may send permission requests to
[email protected].

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of
this publication for use in its laboratory procedure manual at a single site. To request permission to use
this publication in any other manner, e-mail [email protected].

Suggested Citation

CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational
Supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

Twenty-Fourth Informational Supplement Sixteenth Informational Supplement
January 2014 January 2006

Twenty-Third Informational Supplement Fifteenth Informational Supplement
January 2013 January 2005

Twenty-Second Informational Supplement Fourteenth Informational Supplement
January 2012 January 2004

Twenty-First Informational Supplement Thirteenth Informational Supplement
January 2011 January 2003

Twentieth Informational Supplement (Update) Twelfth Informational Supplement
June 2010 January 2002

Twentieth Informational Supplement Eleventh Informational Supplement
January 2010 January 2001

Nineteenth Informational Supplement Tenth Informational Supplement
January 2009 January 2000

Eighteenth Informational Supplement Ninth Informational Supplement
January 2008 January 1999

Seventeenth Informational Supplement
January 2007

ISBN 1-56238-897-5 (Print)
ISBN 1-56238-898-3 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
4
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
Vol. 34 No. 1 M100-S24

Committee Membership

Consensus Committee on Microbiology

Richard B. Thomson, Jr., PhD Thomas R. Fritsche, MD, PhD John D. Turnidge, MD
Chairholder Marshfield Clinic SA Pathology at Women’s and
Evanston Hospital, NorthShore Marshfield, Wisconsin, USA Children’s Hospital
University HealthSystem North Adelaide, Australia
Evanston, Illinois, USA Patrick R. Murray, PhD
BD Diagnostics Jeffrey L. Watts, PhD, RM(NRCM)
John H. Rex, MD, FACP Sparks, Maryland, USA Zoetis, Inc.
Vice-Chairholder Kalamazoo, Michigan, USA
AstraZeneca Pharmaceuticals Kerry Snow, MS, MT(ASCP)
Waltham, Massachusetts, USA FDA Center for Drug Evaluation and Nancy L. Wengenack, PhD,
Research D(ABMM), FIDSA
Nancy L. Anderson, MMSc, Silver Spring, Maryland, USA Mayo Clinic
MT(ASCP) Rochester, Minnesota, USA
Centers for Disease Control and Fred C. Tenover, PhD, D(ABMM)
Prevention Cepheid
Atlanta, Georgia, USA Sunnyvale, California, USA

Subcommittee on Antimicrobial Susceptibility Testing

Jean B. Patel, PhD, D(ABMM) Dwight J. Hardy, PhD Mair Powell, MD, FRCP, FRCPath
Chairholder University of Rochester Medical Center MHRA
Centers for Disease Control and Rochester, New York, USA London, United Kingdom
Prevention
Atlanta, Georgia, USA Janet A. Hindler, MCLS, MT(ASCP) John D. Turnidge, MD
UCLA Medical Center SA Pathology at Women’s and
Franklin R. Cockerill III, MD Los Angeles, California, USA Children’s Hospital
Vice-Chairholder North Adelaide, Australia
Mayo College of Medicine Stephen G. Jenkins, PhD, D(ABMM),
Rochester, Minnesota, USA F(AAM) Melvin P. Weinstein, MD
New York Presbyterian Hospital Robert Wood Johnson Medical School
Jeff Alder, PhD New York, New York, USA New Brunswick, New Jersey, USA
Bayer HealthCare
Whippany, New Jersey, USA James S. Lewis II, PharmD Barbara L. Zimmer, PhD
University of Texas Health Science Siemens Healthcare Diagnostics Inc.
Patricia A. Bradford, PhD Center West Sacramento, California, USA
AstraZeneca Pharmaceuticals San Antonio, Texas, USA
Waltham, Massachusetts, USA
Linda A. Miller, PhD
George M. Eliopoulos, MD GlaxoSmithKline
Beth Israel Deaconess Medical Center Collegeville, Pennsylvania, USA
Boston, Massachusetts, USA

Acknowledgment

CLSI and the Consensus Committee on Microbiology gratefully acknowledge the following individuals
for their help in preparing this document:

Jana M. Swenson, MMSc Maria M. Traczewski, BS,
Consultant MT(ASCP)
Chattahoochee Hills, Georgia, The Clinical Microbiology
USA Institute
Wilsonville, Oregon, USA

5
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
January 2014 M100-S24

Working Group on Methodology

Stephen G. Jenkins, PhD, Laura M. Koeth, MT(ASCP) Ribhi M. Shawar, PhD, D(ABMM)
D(ABMM), F(AAM) Laboratory Specialists, Inc. FDA Center for Devices and
Co-Chairholder Westlake, Ohio, USA Radiological Health
New York Presbyterian Hospital Silver Spring, Maryland, USA
New York, New York, USA Sandra S. Richter, MD, D(ABMM)
Cleveland Clinic John D. Turnidge, MD
Brandi Limbago, PhD Cleveland, Ohio, USA SA Pathology At Women’s and
Co-Chairholder Children’s Hospital
Centers for Disease Control and Darcie E. Roe-Carpenter, PhD, CIC, North Adelaide, Australia
Prevention CEM
Atlanta, Georgia, USA Siemens Healthcare Diagnostics Inc. Melvin P. Weinstein, MD
West Sacramento, California, USA Robert Wood Johnson Medical
Seth T. Housman, PharmD, MPA School
Center for Anti-Infective Research Katherine Sei New Brunswick, New Jersey, USA
and Development, Hartford Hospital Siemens Healthcare Diagnostics Inc.
Hartford, Connecticut, USA West Sacramento, California, USA

Romney M. Humphries, PhD, Susan Sharp, PhD, D(ABMM),
D(ABMM) F(AAM)

UCLA David Geffen School of Kaiser Permanente-NW
Medicine Portland, Oregon, USA

Los Angeles, California, USA

Text and Table Working Group

Jana M. Swenson, MMSc Dyan Luper, BS, MT(ASCP)SM, MB Jeff Schapiro, MD
Co-Chairholder BD Diagnostic Systems Kaiser Permanente
Consultant Sparks, Maryland, USA Alamo, California, USA
Chattahoochee Hills, Georgia, USA
Linda M. Mann, PhD, D(ABMM) Dale A. Schwab, PhD, D(ABMM)
Maria M. Traczewski, BS, MT(ASCP) Consultant Quest Diagnostics, Nichols Institute
Co-Chairholder Sacramento, California, USA San Juan Capistrano, California, USA
The Clinical Microbiology Institute
Wilsonville, Oregon, USA Susan D. Munro, MT(ASCP), CLS Richard B. Thomson, Jr., PhD
Consultant Evanston Hospital, NorthShore
Janet A. Hindler, MCLS, MT(ASCP) Campbell, California, USA University HealthSystem
UCLA Medical Center Evanston, Illinois, USA
Los Angeles, California, USA
Flavia Rossi, MD
Mary K. York, PhD, ABMM
University of Sao Paulo
MKY Microbiology Consulting
Sao Paulo, Brazil
Walnut Creek, California, USA

6
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
Vol. 34 No. 1 M100-S24

Quality Control Working Group

Steven D. Brown, PhD, ABMM Stephen Hawser, PhD Ross Mulder, MT(ASCP)
Co-Chairholder IHMA Europe Sàrl bioMérieux, Inc.
Consultant Epalinges, Switzerland, USA Hazelwood, Missouri, USA
Wilsonville, Oregon, USA
Janet A. Hindler, MCLS, MT(ASCP) Susan D. Munro, MT(ASCP), CLS
Sharon K. Cullen, BS, RAC UCLA Medical Center Consultant
Co-Chairholder Los Angeles, California, USA Campbell, California, USA
Siemens Healthcare Diagnostics Inc.
West Sacramento, California, USA Michael D. Huband Robert P. Rennie, PhD
AstraZeneca Pharmaceuticals University of Alberta Hospital
William B. Brasso Waltham, Massachusetts, USA Edmonton, Alberta, Canada
BD Diagnostic Systems
Sparks, Maryland, USA Ronald N. Jones, MD Frank O. Wegerhoff, PhD,
JMI Laboratories MSc(Epid), MBA
Patricia S. Conville, MS, MT(ASCP) North Liberty, Iowa, USA Seattle, Washington, USA
FDA Center for Devices and Radiological
Health Erika Matuschek, PhD
Silver Spring, Maryland, USA ESCMID
Vãxjõ, Sweden

Staff

Clinical and Laboratory Standards Institute
Wayne, Pennsylvania, USA

Luann Ochs, MS
Senior Vice President – Operations

Tracy A. Dooley, MLT(ASCP)
Staff Liaison

Megan L. Tertel, MA
Editor

Joanne P. Christopher
Assistant Editor
7
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.
January 2014 M100-S24

8
Thisdocumentisprotectedbycopyright.
PublishedOn1/1/2014.